0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
This Month in Archives of Neurology |

This Month in Archives of Neurology FREE

Arch Neurol. 2012;69(10):1237-1238. doi:10.1001/archneurol.2011.1479.
Text Size: A A A
Published online

DEMENTIA RESULTING FROM TRAUMATIC BRAIN INJURY: WHAT IS THE PATHOLOGY?

Shively and colleaguesArticle review the epidemiologic data linking traumatic brain injury and dementia and the existing clinical and pathologic data, and they identify areas where future research is needed.

Place holder to copy figure label and caption

Graphic Jump LocationImage not available.

Histopathologic features of chronic traumatic encephalopathy in a former professional football player (courtesy of Ann McKee, MD, Center for the Study of Traumatic Encephalopathy, Boston University School of Medicine, Boston, Massachusetts). Scanning view of the hippocampus and parahippocampal cortex. Note intense immunostaining of the entire Ammon horn and subiculum with focal involvement at the depths of sulci of the inferior temporal lobe.

POTENTIAL USE OF Γ-SECRETASE MODULATORS IN THE TREATMENT OF ALZHEIMER DISEASE

Wagner et alArticle discuss γ-secretase inhibition and γ-secretase modulation as approaches to disease-modifying therapeutics capable of substantially altering the clinical course of Alzheimer disease and emphasize their significant differences.

IMPACT OF FINGOLIMOD THERAPY ON MAGNETIC RESONANCE IMAGING OUTCOMES IN PATIENTS WITH MULTIPLE SCLEROSIS

Radue and colleaguesArticle report fingolimod therapy resulted in rapid and sustained reductions in inflammatory lesion activity as assessed by gadolinium-enhancing and new/newly enlarged T2 lesions after 6, 12, and 24 months of therapy (P < .001, all comparisons vs placebo).

COMPREHENSIVE SEARCH FOR ALZHEIMER DISEASE SUSCEPTIBILITY LOCI IN THE APOE REGION

Jun et alArticle indicate that APOE alleles ϵ2, ϵ3, and ϵ4 account for essentially all the inherited risk of Alzheimer disease associated with this region. Other variants including a poly-T track in TOMM40 are not independent risk or age at onset loci. Editorial perspective is provided by Rita J. Guerreiro, PhD, and John Hardy, PhDArticle.

FINGOLIMOD IMPEDES SCHWANN CELL–MEDIATED MYELINATION: IMPLICATIONS FOR THE TREATMENT OF IMMUNE NEUROPATHIES?

Köhne and colleaguesArticle show that fingolimod can induce apoptosis in Schwann cells and may interfere with peripheral nerve myelination.

RESULTS OF PHASE 2 SAFETY AND FEASIBILITY STUDY OF TREATMENT WITH LEVETIRACETAM FOR PREVENTION OF POSTTRAUMATIC EPILEPSY

Klein et alArticle provide data in support of further evaluation of levetiracetam treatment for the prevention of posttraumatic epilepsy.

DYING FOR THE WEEKEND: A RETROSPECTIVE COHORT STUDY ON THE ASSOCIATION BETWEEN DAY OF HOSPITAL PRESENTATION AND THE QUALITY AND SAFETY OF STROKE CARE

Palmer and colleaguesArticle report evidence suggesting that the quality for care of stroke patients declines on weekends.

INHIBITION OF INTERFERON-BETA RESPONSES IN MULTIPLE SCLEROSIS IMMUNE CELLS ASSOCIATED WITH HIGH-DOSE STATINS

Feng et alArticle find that high-dose add-on statin therapy significantly reduces interferon-beta function and type 1 interferon responses in relapsing-remitting multiple sclerosis patients.

PLASMA BIOMARKERS ASSOCIATED WITH THE APOLIPOPROTEIN E GENOTYPE AND ALZHEIMER DISEASE

Soares and colleaguesArticle confirm cerebrospinal fluid studies reporting increased levels of pancreatic polypeptide and N-terminal protein B–type brain natriuretic peptide in patients with Alzheimer disease and mild cognitive impairment.

BLOOD-BASED PROTEIN BIOMARKERS FOR DIAGNOSIS OF ALZHEIMER DISEASE

Doecke et alArticle identify a panel of plasma biomarkers that distinguish individuals with Alzheimer disease from cognitively healthy control subjects with high sensitivity and specificity.

PATHOLOGIC ACCUMULATION OF Α-SYNUCLEIN AND AΒ IN PARKINSON DISEASE PATIENTS WITH DEMENTIA

Kotzbauer and colleaguesArticle provide data indicating that dementia associated with Parkinson disease has 2 major pathologic subgroups: neocortical synucleinopathy and neocortical synucleinopathy with Aβ deposition.

ASSOCIATION OF SHORTER LEUKOCYTE TELOMERE REPEAT LENGTH WITH DEMENTIA AND MORTALITY

Honig et alArticle suggest that shortened leukocyte telomere length is associated with risks for dementia and mortality and may therefore be a marker of biological aging.

DIFFUSION TENSOR IMAGING OF VASCULAR PARKINSONISM: STRUCTURAL CHANGES IN CEREBRAL WHITE MATTER AND THE ASSOCIATION WITH CLINICAL SEVERITY

Wang and colleaguesArticle suggest that the disruption of the microstructural organization of frontal lobe white matter is associated with the severity of vascular parkinsonism.

First Page Preview

View Large
First page PDF preview

Figures

Place holder to copy figure label and caption

Graphic Jump LocationImage not available.

Histopathologic features of chronic traumatic encephalopathy in a former professional football player (courtesy of Ann McKee, MD, Center for the Study of Traumatic Encephalopathy, Boston University School of Medicine, Boston, Massachusetts). Scanning view of the hippocampus and parahippocampal cortex. Note intense immunostaining of the entire Ammon horn and subiculum with focal involvement at the depths of sulci of the inferior temporal lobe.

Tables

References

Correspondence

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

588 Views
0 Citations
×

Related Content

Customize your page view by dragging & repositioning the boxes below.

Jobs